

31 March 2025

Press Release

EFPIA Japan

Reappointment of Chair and Vice Chair

TOKYO –31 March 2025 – European Federation of Pharmaceutical Industries and Associations (EFPIA Japan) announced that Takahiko Iwaya (Sanofi K.K.) has been reappointed Chair, and Takafumi Horii (AstraZeneca K.K.) and Kasper Bødker Mejlvang (Novo Nordisk Pharma Ltd.) have been reappointed Vice Chair respectively effective 27 March. Their term is until March, 2027.

“ Japan’s pharmaceutical industry is in a period of transformation, and it is urgent to rebuild the healthcare system and environment to continue to deliver breakthrough medicines and vaccines to patients in Japan. We will continue to discuss with stakeholders to ensure the growth of the pharmaceutical market in Japan and access to the latest healthcare solutions for patients.” says Takahiko Iwaya upon his reappointment.

EFPIA Japan Board Members as of 27 March 2025

Chair	Takahiko Iwaya	Sanofi K.K.
Vice Chair	Takafumi Horii	AstraZeneca K.K.
	Kasper Bødker Mejlvang	Novo Nordisk Pharma Ltd.
Board of Directors	Ying Chen	Bayer Yakuhin, Ltd.
	Paul Lirette	GlaxoSmithKline K.K.
	Jeremy Grossas	Merck Biopharma Co., Ltd.
	Jan Stefan Scheld	Nippon Boehringer Ingelheim Co., Ltd.
	John Paul Pullicino	Novartis Pharma K.K.
	Kanako Kikuchi	UCB Japan Co., Ltd.
Director General	Yoshiaki Aono	

About EFPIA Japan (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceutical companies operating in Japan. In 2023, combined sales from the member companies accounted for roughly 28% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations) (<http://www.efpia.eu>)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 40 leading pharmaceutical companies, and a growing number of small and medium sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop, and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.

Contact:

Yukie Shimono

EFPIA Japan External Affairs Committee

Tokyo Opera City Tower, 3-20-2 Nishi Shinjuku, Shinjuku-ku, Tokyo 163-1488, Japan Sanofi K.K.

Tel: 090-2736-8171

Email: yukie.shimono@sanofi.com